MSL3 Syndrome

09/09/2026

Your MSL3 Syndrome Foundation representatives are excited to attend the Rare Drug Development Symposium presented by Global Genes. We are learning how to advance our advocacy and move the MSL3 community toward efficient research in pursuit of our patient support and treatment goals.

09/09/2026

RESEARCH ACCELERATION PROGRAM OUTPUT REPORT SUMMARY part 4

4. Main Gaps and Recommended Next Steps

The report concludes that the largest barriers are incomplete knowledge of the condition, limited research tools, and a lack of long-term information about how MSL3 syndrome changes from childhood into adulthood. There are no validated biomarkers, meaning there is no established laboratory measure that can reliably track the condition or show whether a treatment is working. There are also no MSL3-specific clinical-trial outcome measures. More consistent information about movement, learning, behavior, quality of life, and health over time is needed before strong clinical trials can be designed.

The report gives three highest-priority recommendations: hold a combined scientific and patient conference to increase collaboration; study whether an MSL3-specific animal model can be developed; and use patient-derived cells to screen possible drugs and revisit earlier HDAC-inhibitor findings. Additional suggested work includes expanding patient registries, collecting and storing samples such as skin, blood, and cells, studying how different gene changes relate to symptoms, developing brain organoid models, and identifying clinical specialists and consistent health measures. Because the condition is very rare, the report emphasizes that international teamwork among families, patient advocates, clinicians, and researchers will be essential.

09/09/2026

RESEARCH ACCELERATION PROGRAM OUTPUT REPORT SUMMARY part 3

3. What Researchers Are Learning and Why Treatment Is Difficult

The MSL3 gene helps form a cell system called the MSL complex. This system helps control how genes are turned on by adding a chemical marker called H4K16ac to proteins that package DNA. Changes in MSL3 can weaken this system, reduce this marker across the genome, and interfere with normal gene activity that is important for brain development. The report also describes early evidence that these changes may affect parts of DNA known as transposable elements, which can help control nearby genes. However, the full chain of events that causes the condition is still not known.

Research has important limitations. Scientists do not yet have a well-established animal model that closely reflects MSL3 syndrome in people, and there is no standardized set of patient-derived cell models for broad research use. Earlier work found that certain drugs called HDAC inhibitors partly restored the H4K16ac marker and improved a cell behavior in patient-derived cells. That result is an early research finding, not proof of a safe or effective treatment for people. Other ideas, including increasing MSL3 activity or replacing the gene, remain theoretical and need much more laboratory research before they can be tested clinically.

09/09/2026

RESEARCH ACCELERATION PROGRAM OUTPUT REPORT SUMMARY part 2

2. Health Features, Diagnosis, and Current Care

People with MSL3 syndrome can have a range of developmental, neurological, and physical features. Commonly reported concerns include delayed development, intellectual disability, speech and language difficulties, low muscle tone, delayed walking, hearing impairment, constipation or reflux, and a larger-than-average head size. Some individuals have seizures, autism-related features, attention or behavior challenges, or increasing muscle stiffness that can affect walking. Physical features can vary, and some people may also have growth differences, joint flexibility, scoliosis, or less commonly heart or urinary-system differences.

A diagnosis cannot be confirmed by symptoms alone because MSL3 syndrome overlaps with other developmental disorders. The report states that genetic testing, usually whole-exome or whole-genome sequencing, is needed to confirm an MSL3-related diagnosis. There is currently no treatment designed specifically for MSL3 syndrome. Care is supportive and individualized, and may include speech, occupational, and physical therapy; seizure monitoring and treatment; behavioral support; educational planning; and help with feeding, nutrition, growth, and other ongoing needs.

09/09/2026

RESEARCH ACCELERATION PROGRAM OUTPUT REPORT SUMMARY part 1

1. Purpose of the Report and What Is Known About MSL3 Syndrome

This report reviews how ready the MSL3 community is to support research that could eventually lead to treatments and clinical trials. It examines four areas: understanding the biology of the condition, readiness to test possible treatments, readiness for clinical trials, and patient and family participation. The report was prepared for the MSL3 community using published research and input from medical and scientific experts. It identifies major gaps and recommends practical projects that could help move research forward.

MSL3 syndrome, also called Basilicata-Akhtar syndrome, is an ultra-rare condition that affects brain development. It is caused by changes in the MSL3 gene, which is located on the X chromosome. About 100 people worldwide are known to have been diagnosed, but the report notes that more people may have the condition because it was only identified recently and its features can overlap with other developmental conditions. It has been reported in people from several parts of the world and appears to affect males and females in similar ways, although the reasons for this are not fully understood.

09/09/2026

We are excited to share the Research Acceleration Program Output Report. Global Genes and Rare-X, along with the MSL3 Syndrome Foundation, collaborated with the researchers and scientists committed to understanding MSL3 Syndrome and advancing research about the disease. We are pleased with the final report and a roadmap towards meaningful projects that will benefit our whole community.

Stay tuned for our summary breakdowns of this important document so we can understand the report and future projects together.

Research Acceleration Program Output Report July 9th, 2026 Prepared By: Prepared For: Karmen Trzupek, MS, CGC MSL3 Community Catherine Strandt, DMSc TABLE OF CONTENTS Key Opinion Leader Advisory List..............................................................................................

05/03/2026

HAPPY MSL3 DAY!
Sending love to our community around the world ❤️

05/01/2026

MSL3 Day is May 3rd!

How are you planning to celebrate 🎉
(Share in comments)

02/28/2026

Happy Rare Disease Day!
Today we celebrate our ultra-rare MSL3 family along with the rare disease community in general.

Care about rare!

02/02/2026

We are progressing through our Research Readiness initiative and have received consistent feedback about the importance of joining our Data Collection Program (linked here). Even if you can just upload your genetic report, the impact is significant. Looking forward sharing more concrete updates soon!
https://rare-x.org/msl3syndrome/?fbclid=IwVERFWAPuAghleHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEe5dUVANdI_dHArZMLtiZIekPWxVXiidn2CnLn1vhQtSjW1mee0phIBm9epcI_aem_dut4Fj7JevdDwgIANVHKtQ

MSL3 Syndrome - Data Collection Program MSL3 Syndrome patients, families, and communities are excited to participate in data collection to expand and improve medical research. By coming to this site, you can begin the first step in making your patient information available to researchers. By generat...